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Urodynamic evaluation of acute effects of sildenafil on voiding
among males with erectile dysfunction and
symptomatic benign prostate
Fatih Rüştü YALÇINKAYA, Mürsel DAVARCI, Soner AKÇİN, Ahmet GÖKÇE,
Eşref Oğuz GÜVEN, Mehmet İNCİ, Mevlana Derya BALBAY

Aim: To evaluate the acute effects of sildenafil citrate on micturition of men with erectile dysfunction and symptomatic
benign prostatic hyperplasia using urodynamic parameters.
Materials and methods: Between June and December 2009, a total of 50 patients over the age of 40 participated in
the study. The patients were admitted to our hospital with erectile dysfunction and moderate to severe lower urinary
symptoms with benign prostatic hyperplasia. To examine the sexual function of the participants, we used the IIEF-5
Sexual Health Inventory for Men questionnaire. Patients were randomly divided into 2 groups: a treatment group and a
control group. A basal urodynamic evaluation was performed in both groups. After the urodynamic evaluation, 50 mg
of sildenafil was given to the patients in the control group and 1 h later a second evaluation was performed. Following
the urodynamic evaluation, a placebo was given to the patients in the control group and then a second evaluation was
performed after 1 h.
Results: A statistically significant increase was seen in maximal flow and average flow (Qmax and Qave) after 1 h in the
treatment group. The increase in the control group was not significant.
Conclusion: Based on the study findings, we suggest that sildenafil has an effect on micturition in the short term.
However, to determine the role of sildenafil in the treatment of BPH/LUTS, further studies with larger patient groups
are needed.
Key words: Benign prostatic hyperplasia, lower urinary tract symptoms, phosphodiesterase inhibitors, sildenafil,
uroflowmetry, urodynamics

Introduction
Benign prostate hyperplasia (BPH) is enlargement
of the prostate (1). Erectile dysfunction (ED) is
defined as a deficiency in sustaining or maintaining
enough penile erection for sexual intercourse for
at least 6 months (2). BPH and ED are common
disorders among aging males (3,4). The presence
of lower urinary tract symptoms (LUTS) related to
BPH is defined as an independent risk factor for
the development of ED (5). In BPH, lower urinary
tract symptoms develop partly as a result of partly

fast growing prostate and bladder outlet obstruction
(static component), and partly due to bladder
decompensation and hyperfunction (dynamic
component) (3).
Several studies have demonstrated that treatment of
ED patients with sildenafil such as phosphodiesterase
5 (PDE5) not only treats ED symptoms but also
LUTS (6,7). The highest PDE5 expression, after the
corpus cavernousum, is in the bladder. However,
there is also an important PDE5 expression in the
prostate (8). For this reason, it is thought that PDE5
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has a functional effect on these tissues (9). Uckert
et al. demonstrated PDE5 presence in the human
prostate transitional zone (10). PDE5 inhibitors
clearly cause relaxation in the bladder, prostate, and
urethral tissues. This seems more effective in the
prostate and urethra. The relaxation of the prostate
and urethra can decrease urinary outflow resistance
and can regulate urine flow (6,9). In previous studies,
chronic treatment of BPH patients with PDE5
inhibitor has been the focus. Consequently, the
acute effect of PDE5 inhibitors was not evaluated.
In a study carried out with uroflowmetry, it was
shown that sildenafil has a positive effect on low
urinary system obstruction when it is at maximum
blood rate (11). Uroflowmetry (though it is the most
common, practical, and objective lower urinary
system obstruction evaluation tool) has a wide
unstable range and no reproducibility. Pressure-flow
studies, an invasive type of urodynamic studies, are
carried out by calculating flow-rate during voiding
on uroflowmetry along with calculating detrusor
pressure. At present, pressure-flow study is accepted
as the gold standard in the diagnosis of infravesical
obstruction (12).
Therefore, our aim was to investigate the effect of
sildenafil citrate on LUTS in BPH patients with ED.
Materials and methods
The study was planned as single center, prospective,
randomized, and placebo controlled, after obtaining
permission from the Ethical Committee of Mustafa
Kemal University Medical School. Between June
and December 2009, 50 patients over the age of 40
who had ED and lower urinary symptoms, ranging
from medium levels to acute levels, according to the
International Prostate Symptom Score (IPSS), were
included in the study. A signed, written informed
consent, approved by the local Ethical Committee,
was obtained from all subjects before the study.
Detailed medical history of each patient was
obtained for basal evaluation. A full physical
examination, including a digital rectal examination,
was performed. Total and free serum prostate
specific antigen (PSA) levels were determined.
Abdominopelvic
ultrasonography
was
also
performed. LUTS were evaluated with IPSS. To
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determine the sexual functions of the patients, the
IIEF-5 Sexual Health Inventory for Men survey
was used by summing up the International Index of
Erectile Function (IIEF) survey (13). This survey is
useful because it has 5 questions and can be answered
by the patients in a few minutes. The IIEF, which was
developed by Rosen et al., is one of most common
forms used for evaluating sexual problems in men
(14).
To be involved in the study, the IIEF-5 score
had to be below 21 and the total IPSS score had
to be over 7. Exclusion criteria were as follows:
history of erectogenic treatment, any treatment
for LUTS (α-blocker or 5 α-reductase inhibitor),
urethral stricture, bladder tumor, renal insufficiency,
neurogenic bladder, cardiovascular and pulmonary
disorder, urinary infection, urinary stone disease,
diabetes mellitus, previous prostate operation,
previous pelvic operation, elevated levels of prostate
specific antigen (PSA), and abnormal digital rectal
examination.
The patients were randomly separated into
treatment and control groups (30 patients taking 50
mg of oral sildenafil in the first group and 20 patients
taking a placebo in the second group). In both groups,
basal urodynamic evaluations were performed. In
the treatment group, following the urodynamic
evaluation, 50 mg oral sildenafil citrate tablets were
given, and 1 h later a second urodynamic evaluation
was performed. On the other hand, in the control
group, a placebo was given after the first urodynamic
evaluation, and 1 h later a second evaluation was
performed. All patients, before urodynamics,
were subject to uroflowmetry and postmicturition
residual urine determination following spontaneous
voiding. Following this, the patients underwent
pressure flow studies in both sitting and standing
postures. Detrusor contractility pressure during the
maximum flow voiding, maximum urinary flowing
speed, average flowing speed, and electromyography
activity during voiding were recorded (Table 1).
Statistical analysis
A t-test was used to compare the ages, prostate
volumes, PSA, duration of symptoms, IPSS, quality
of life, and IIEF of all patients. Differences between
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Table 1. Patients’ characteristics for both groups.

Group 1 (n = 30) mean ± SD

Group 2 (n = 20) mean ± SD

P value (<0.05 significant)

Age

58.63 ± 10.56

55.2 ± 9.19

0.376

Prostate volume (cm3)

51.93 ± 15.01

46.3 ± 12.12

0.084

PSA (ng/dL)

1.89 ± 1.07

1.61 ± 0.77

0.84

Symptom duration (month)

3.43 ± 0.5

3.4 ± 0.5

0.641

19.16 ± 6.06

16.9 ± 4.08

0.139

3.3 ± 0.74

2.75 ± 0.71

0.058

10.83 ± 5.88

9.45 ± 4.99

0.065

IPSS
Quality of life
IIEF

predrug basal urodynamic parameters and postdrug
urodynamic parameters were evaluated using a
nonparametric test (Wilcoxon marked rank test). P <
0.05 considered significant.
Results
In the treatment group, the predrug basal mean Qmax
(maximum flow rate) was 8.7 ± 3.54 mL/s, while it
was 11.56 ± 6.82 mL/s in the first hour postdrug. This
difference was statistically significant (P < 0.05). In
the control group, the basal mean Qmax was 7.35 ±
2.73 mL/s, while it was 7.6 ± 3.26 mL/s in the first
hour postdrug. The difference was not significant (P
> 0.05) (Figure 1).
In the treatment group, the predrug mean Qave
(average flow rate) was 4.72 ± 1.88 mL/s, while it

was 5.8 ± 2.7 mL/s in the first hour postdrug. This
difference was statistically significant (P < 0. 05). In
the control group, the mean Qave predrug was 3.8
± 1.28 mL/s, while it was 3.9 ± 1.44 mL/s in the first
hour postdrug. The difference was not statistically
significant (P > 0. 05) (Table 2).
According to the nonparametric Wilcoxon marked
rank test statistical analysis (P > 0.05), there was no
statistical significance between the groups, regarding
first urine feeling, first jamming feeling, bladder
volume, bladder compliance, vesicle pressure in
discharging, abdominal pressure, detrusor pressure,
electromyography, predrug basal urodynamic rate,
and postdrug urodynamic rates in terms of voiding
volume.
Discussion

14
12
10
Qmax in group 1

8

Qmax in group 2
6

Qave in group 1
Qave in group 2

4
2
0
Predrug

Postdrug

Figure 1. Pre- and postdrug flow rate in both groups.

Both LUTS and BPH are seen in similar groups.
Along with this, the mechanisms to explain the
process of these diseases are not well known. Chang
et al. drew attention to the possible mechanisms of
ED development in BPH patients based on a rabbit
model, which had partial bladder outlet obstruction
(15).
The beneficial effects of PDE5 inhibitors on
bladder hyperactivity are clearly reported (6,9,16).
The LUTS patients with ED are still looking for
medical help. The first step in treatment for ED is oral
PDE5 inhibitors. Treatment with phosphodiesterase
type 5 (PDE5) is an effective and reliable treatment
for erectile dysfunction (17-19).
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Table 2. Pre- and postdrug flow rate in both groups.

Group 1 (mL/s)
Group 2 (mL/s)

Predrug

Postdrug

Qmax

8.7 ± 3.54

11.56 ± 6.82

Qave

4.72 ± 1.88

11.5 ± 2.7

Qmax

7.35 ± 2.73

7.6 ± 3.26

Qave

3.8 ± 1.28

3.9 ± 1.4

Sildenafil is the first PDE5 inhibitor. The suggested
starting dose is 50 mg, and this should be regulated
according to the patient’s response and side effects
(20).
To date, 11 members of PDE type have been
described. cAMP and cGMP constructed with
PDE inhibitors mediate prostatic smooth muscle
relaxation (21,22).
When compared with the corpus cavernosum,
there was high PDE5 mRNA expression in the
bladder and urethra. However, at the same time,
there was a significant amount of PDE5 expression in
the prostate (8), which is why the functional role of
PDE5 can be seen in these tissues (9).
Uckrert et al. showed the effect of PDE5 in the
prostate transitional zone. Most commonly found
was PDE4, while the second most common was
PDE5. They also showed that sildenafil is a relaxant
mediated by an agent in the transitional zone bands
of the prostate (10). These findings make us think
that sildenafil has a positive effect on the prostate
smooth muscle cells.
The other cause of the obstruction is a growing
prostate. Obstruction is a mechanized cause. New
reports make us think that cGMP accumulation has
an antiproliferative effect on the smooth muscle cells
of the prostate (23,24). A previous study showed
that Zaprinast can decrease proliferation in smooth
muscle cells and prostatic stromal cells of patients
with BPH (25). The PDE5 inhibitors on the market
were shown to have an antiproliferative effect on
BPH smooth muscle cells (8,23). In a study carried
out by Dokita et al., it was found that Zaprinast, a
PDE5 inhibitor, increases urethral relaxation in
rabbits (26).
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P ≤ 0.05
P ≥ 0.05

Qui et al. found that sildenafil caused a small but
meaningful increase in cGMP on the detrusor muscle
in rabbits. At the same time, the cGMP level alone is
not enough. The detrusor smooth muscle is usually
mediated by cAMP. The researchers accepted that
sildenafil probably caused the relaxant effect through
PDE1 inhibition. At the same time, they stated that
they could not ignore cGMP necessity for effective
relaxation (27).
Another mechanism claimed to decrease LUTS is
to increase nitric oxide (NO) transmission with PDE5
inhibitors and, in this way, to regulate nonvoiding
contractions (hyperactivity) (16,28,29).
Although there is increasing proof of the positive
effects of PDE5 inhibitors on LUTS, in none of these
studies has the short-term effect of these drugs on the
voiding of men with BPH been found.
In the study by Kaplan et al., Qmax results showed a
positive improvement although it was not statistically
significant (30). The common point in clinical studies
that showed the positive effect of sildenafil on LUTS
is that all of the findings were collected from patients
who used sildenafil for at least for 1 month (7).
These long-term positive effects indicate that
PDE5 depended on antiproliferative and relaxant
effects, and relaxant effects on the bladder and
urethra. NO is an important mediator on isolated
bladder and urethra smooth muscle and, at the same
time, it regulates prostatic smooth muscle tones. For
this reason, the increasing level of NO after sexual
functions can be responsible for the improvement in
LUTS. Independent from these factors, it is known
that improvement in the sexual lives of the patients
increases quality of life and this can indirectly
improve LUTS.
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It has been shown that sildenafil increases the
prostate blood flow by 75% (31). The stimulation
of an erection can cause prostatic congestion, and
this unwanted condition may cause sudden voiding
trouble.
In all of these studies, the focus has been on
the chronic treatment of BPH patients with PDE5
inhibitors. Incidentally the acute effects of PDE5
inhibitors were not wholly evaluated. In our study,
we aimed to show the acute effect on urodynamic
parameters of 50 mg oral sildenafil in patients who
have BPH-LUTS and ED combinations. Since our
patients took only one dose of sildenafil, it is difficult
to comment on the positive effects on IPSS, possible
side effects, or effects if used in combination with
other drugs.
In a pilot study carried out on 38 BPH patients and
15 healthy volunteers the acute effects of sildenafil on
uroflowmetric parameters (32) were examined. The
participants were asked to hold their voiding until
the bladder was full, and they were then given 100 mg
of oral sildenafil. Half an hour later, uroflowmetric
evaluations were performed. Maximum and average
flowing rates were remarkably high in patients with
BPH after sildenafil treatment. Moreover, after
sildenafil treatment, average voiding duration was
clearly shorter. In the control group, there were no
evident changes in uroflowmetric parameters before
and after sildenafil treatment.
Pressure-flowing, an invasive urodynamic
study, is carried out by measuring flowing speed
lost in uroflowmetry during voiding along with
measuring detrusor pressure. Nowadays, pressureflowing studies are accepted as the gold standard for
infravesical obstruction diagnosis (12,33).
In our study, the basal and first-hour urodynamic
parameters of the sildenafil group (group 1) and
placebo group (group 2) were evaluated. In the first
group, Qmax and Qave rates were clearly increased
after 1 h and this increase was statistically significant

(P < 0.05). In the second group, these rates also
increased, but they were not statistically significant
(P > 0.05). There was no statistically significant
difference between predrug basal urodynamic values
and postdrug first-hour urodynamic values (P >
0.05). These results were similar to those of 2 previous
pilot studies. In both of the groups, regarding first
voiding feeling, bladder volume, bladder compliance,
vesical pressure in outflowing, detrusor pressure,
electromyography, abdominal pressure, and voiding
volume, there was no significant difference between
predrug basal urodynamic values and postdrug first
hour urodynamic values (P > 0.05).
Our study differed from other long-term studies
in that no difference in Qmax was found when the
urodynamic calculations were carried out when the
drug reached its maximum blood concentration.
This may be a possible explanation for why the Qmax
improved.
Conclusion
In this study, the acute effect of sildenafil citrate
on the voiding of patients with ED having BPH/
LUTS was evaluated with urodynamic parameters.
In patients who took sildenafil, both the Qmax and
the Qave showed significant increases 1 h after the
drug intake. The increases in the placebo group were
not found to be significant. For this reason, we claim
that sildenafil has an effect on voiding in the acute
stage. The improvement in the sildenafil group, when
compared with the findings from the placebo group,
is supported and is not a measurement variation.
It was seen that sildenafil was not harmful during
voiding, and it even helped patients with ED-BPH
(LUTS) to void. Hence, it can be safely recommended
for this patient group for daily application. Finally,
more research with larger patient groups is needed
in order to define the role of sildenafil in BPH-LUTS
treatment.
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